This study is in progress, not accepting new patients
A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037)
Unresectable or Metastatic Melanoma Melanoma Paclitaxel Carboplatin Nivolumab Dacarbazine BMS-936558 BMS-936558 3 mg/kg (IV)
Lead Scientist at UCSF
- Adil Daud
Professor, Medicine. Authored (or co-authored) 184 research publications.